Nov 18 2008
Oncolytics Biotech Inc. today announced that it has been granted its 30th U.S. Patent, # 7,452,723, entitled "Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders.
"The allowed claims relate to kits comprised of reovirus and an immune suppressive agent that are designed to prevent reovirus recognition by the immune system.
"This U.S. patent covers assemblies which can be used to potentially improve therapeutic benefit to patients, and broadens our coverage in the area of combination treatment," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.